{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:35:45Z","timestamp":1740116145212,"version":"3.37.3"},"reference-count":29,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1949,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1111\/j.1365-2710.2009.01122.x","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T00:57:04Z","timestamp":1274144224000},"page":"no-no","source":"Crossref","is-referenced-by-count":2,"title":["Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls"],"prefix":"10.1155","author":[{"given":"C. P.","family":"Babalola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Adejumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Odetunde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kotila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Falusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ajh.21057","article-title":"Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management","volume":"83","author":"Aliyu","year":"2008","journal-title":"American Journal of Hematology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1086\/314959","article-title":"Plasmodium falciparum infection: influence on hemoglobin levels in alpha-thalassemia and microcytosis","volume":"180","author":"Mockenhaupt","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB3|cit3","article-title":"Malaria chemoprophylaxis in sickle cell disease","volume":"4","author":"Oniyangi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB4|cit4","first-page":"22","article-title":"Proguanil versus pyrimethamine in long and short term malaria chemoprophylaxis in sickle cell disease patients and pregnancy","volume":"1","author":"Adejumo","year":"2002","journal-title":"Nigerian Journal of Pharmaceutical Research"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB5|cit5","first-page":"7","article-title":"Treatment and prevention of Plasmodium falciparum malaria","volume":"1","author":"Bhatt","year":"1994","journal-title":"African Journal of Medical Practice"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/1681080a0","article-title":"A metabolite of paludrine with high antimalarial activity","volume":"168","author":"Carrington","year":"1951","journal-title":"Nature"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2125.1995.tb04474.x","article-title":"The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides","volume":"39","author":"Wright","year":"1995","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/DMR-120023681","article-title":"PM frequencies of major CYPs in Asians and Caucasians","volume":"35","author":"Mizutani","year":"2003","journal-title":"Drug Metabolism Reviews"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1985.194","article-title":"Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations","volume":"38","author":"Nakamura","year":"1985","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2125.1999.00009.x","article-title":"Genetic polymorphism of (S)-mephenytoin 4\u2032-hydroxylation in populations of African descent","volume":"48","author":"Xie","year":"1999","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"De Morais","year":"1994","journal-title":"Molecular Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"De Morais","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00228-002-0509-7","article-title":"Polymorphic oxidative metabolism of proguanil in a Nigerian population","volume":"58","author":"Bolaji","year":"2002","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2125.1994.tb04241.x","article-title":"Oxidative activation of proguanil and dapsone acetylation in Thai soldiers","volume":"37","author":"Edstein","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(05)62696-7","article-title":"High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu","volume":"349","author":"Kaneko","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-3156.1999.00386.x","article-title":"The contribution of alpha+ -thalassaemia to anaemia in a Nigerian population exposed to intense malaria transmission","volume":"4","author":"Mockenhaupt","year":"1999","journal-title":"Tropical Medicine and International Health"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0076-6879(96)72025-6","article-title":"Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism","volume":"272","author":"Goldstein","year":"1996","journal-title":"Methods in Enzymology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0009-9236(98)90037-6","article-title":"Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects","volume":"63","author":"Lamba","year":"1998","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/tpbi.2002.1613","article-title":"Hardy-Weinberg equilibrium diagnostics","volume":"62","author":"Ragatko","year":"2002","journal-title":"Theoretical Population Biology"},{"volume-title":"Hardy-Weinberg Diagnostics (HWDIAG) Version 2.0","year":"2005","author":"Ragatko","key":"10.1111\/j.1365-2710.2009.01122.x-BIB21|cit21"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2125.1993.tb04204.x","article-title":"Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark","volume":"36","author":"Brosen","year":"1993","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1365-2125.1998.00807.x","article-title":"Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population","volume":"46","author":"Hoskins","year":"1998","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0035-9203(96)90531-3","article-title":"Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro","volume":"90","author":"Edstein","year":"1996","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB25|cit25","first-page":"317","article-title":"Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations","volume":"9","author":"Kaneko","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0009-9236(96)80008-7","article-title":"Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians","volume":"59","author":"Skjelbo","year":"1996","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2125.2003.01937.x","article-title":"Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations","volume":"56","author":"Allabi","year":"2003","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-004-0890-5","article-title":"Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study","volume":"61","author":"Bravo-Villalta","year":"2005","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2009.01122.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002280100282","article-title":"Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients","volume":"57","author":"Dandara","year":"2001","journal-title":"European Journal of Clinical Pharmacology"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2009.01122.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2009.01122.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T22:37:26Z","timestamp":1740091046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2009.01122.x"}},"subtitle":["CYP2C19 genotypes in Nigerian population"],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01122.x","relation":{},"ISSN":["0269-4727","1365-2710"],"issn-type":[{"type":"print","value":"0269-4727"},{"type":"electronic","value":"1365-2710"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}